In line with the results from NAMPT inhibition by FK866 and genetic NAMPT reduction in Nampt+/− mice, administration of eNAMPT mAb did not result in alterations to glucose tolerance, body weight or lipid profiles in diabetic mice (Fig. 3e–g and Table 1), but restored coronary microvascular function in diabetes, as evidenced by restoration of the CFVR (Fig. 3h). This evidence concerns the gene NAMPT and diabetes mellitus.